Press Releases Archives | Page 50 of 116

Sartorius collaborates with RoosterBio to advance downstream purification processes for the manufacture of exosomes

January 15, 2023 By Cade Hildreth, Founder & President Leave a Comment

Through this collaboration, Sartorius and RoosterBio will provide best-in-class solutions and expertise for a human mesenchymal stem/stromal cell (hMSC) – based exosome production platform that delivers industry-leading yield, purity, and potency.

FREDERICK, Md., Jan. 5, 2023 – The life science group Sartorius extended a strategic collaboration partnership agreement with RoosterBio Inc. (RoosterBio) to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies. Through this collaboration, Sartorius and RoosterBio will provide best-in-class solutions and expertise for a human mesenchymal stem/stromal cell (hMSC) – based exosome production platform that delivers industry-leading yield, purity, and potency. [Read more…]

FUJIFILM Cellular Dynamics Announces License Agreement with Novo Nordisk for the Development of iPSC-Derived Cell Therapies

January 13, 2023 By Cade Hildreth, Founder & President Leave a Comment

MADISON, WIS., January 5, 2023 – FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), announced that it has entered an agreement to grant global healthcare company Novo Nordisk A/S a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development and commercialization of iPSC-derived cell therapies with a focus on addressing serious chronic diseases. [Read more…]

European Approval Makes Atara’s Ebvallo™ First Allogeneic T-Cell Therapy Approved Worldwide

January 3, 2023 By Cade Hildreth, Founder & President Leave a Comment

Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD

Represents First Approval of an Allogeneic T-Cell Immunotherapy Globally

Pierre Fabre to Lead Commercialization and Distribution Activities in Europe

[Read more…]

I Peace, Inc. honored in BioSpectrum Asia Excellence Award 2022 with “Special Recognition in Cell Therapy”

December 22, 2022 By Cade Hildreth, Founder & President Leave a Comment

PALO ALTO, Calif., Dec. 21, 2022 — I Peace, Inc. has been awarded a “Special Recognition in Cell Therapy” during BioSpectrum Asia Excellence Award 2022 ceremony held in Singapore on December 2.

I Peace, Inc. is a Palo Alto-based biotech company focusing on Nobel Prize-winning technology of induced pluripotent stem cells (iPSCs) and has successfully developed a novel system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-sized closed cassette. I Peace supports research institutions and pharmaceutical companies around the globe by providing clinical-grade iPSCs conforming with regulatory standards both in the U.S. and Japan. [Read more…]

iPSirius Wins $2M Award from European Innovation Council to Develop a Novel Stem Cell Vaccine to Help Cancer Patients Worldwide

December 19, 2022 By Cade Hildreth, Founder & President 1 Comment

iPSirius is creating a new frontier in stem cell-based cancer therapeutics by developing a vaccine to fight aggressive tumors.

Paris, France, 19^th December 2022 – iPSirius is a European immunotherapy company that is working to bring a new range of off-the-shelf vaccines to cancer patients worldwide to improve their prognosis and quality of life. iPSirius has developed a pipeline of engineered induced pluripotent stem cell (iPS) vaccines using its proprietary iPVAC technology. [Read more…]